Silvia Damian

Fondazione IRCCS Istituto Nazionale dei Tumori

Research Interests

Explore related searches

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (13)

Collaborators (6)

Tomoya Yokota

Aichi Cancer Center

Giancarlo Pruneri

University of Milan

Adele Busico

Fondazione IRCCS Istituto Nazionale dei Tumori

Gian Paolo Dagrada

Fondazione IRCCS Istituto Nazionale dei Tumori

Monica Niger

Fondazione IRCCS Istituto Nazionale dei Tumori

Fabio Bozzi

Fondazione IRCCS Istituto Nazionale dei Tumori

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Silvia Damian

Research Interests

Explore related searches

Contact this professor

Articles (13)

Collaborators (6)

Tomoya Yokota

Giancarlo Pruneri

Adele Busico

Gian Paolo Dagrada

Monica Niger

Fabio Bozzi

Make your next move.

Silvia Damian

Research Interests

Explore related searches

Contact this professor

Articles (13)

Publisher Correction: Pemigatinib in previously treated solid tumors with activating FGFR1–FGFR3 alterations: phase 2 FIGHT-207 basket trial

Pemigatinib in previously treated solid tumors with activating FGFR1–FGFR3 alterations: phase 2 FIGHT-207 basket trial

Immunological characterization of a long-lasting response in a patient with metastatic triple-negative breast cancer treated with PD-1 and LAG-3 blockade

Molecular Tumor Board as a Clinical Tool for Converting Molecular Data Into Real-World Patient Care

Phase II study on safety and efficacy of NMS-01940153E, an MPS1 inhibitor with first-in-class potential, in adult patients with unresectable hepatocellular carcinoma (HCC) previously treated with systemic therapy.

77P BRCA mutations may induce immune-resistance in breast cancer patients treated with IO-only approach: A retrospective analysis

Abstract CT016: Clinical and translational findings of pemigatinib in previously treated solid tumors with activating <i>FGFR1-3</i> alterations in the FIGHT-207 study

Ascites During Selpercatinib Treatment: Need for a Multidisciplinary Approach

Neutralizing antibodies to Omicron after the fourth SARS-CoV-2 mRNA vaccine dose in immunocompromised patients highlight the need of additional boosters

Targeted RNA-sequencing analysis for fusion transcripts detection in tumor diagnostics: assessment of bioinformatic tools reliability in FFPE samples

NMS-01940153E, an MPS1 inhibitor with anti-tumor activity in relapsed or refractory unresectable Hepatocellular carcinoma

Abstract 1269: Negative ultra-selection of patients with <i>RAS</i>/<i>BRAF</i> wild-type (wt), microsatellite stable (MSS) metastatic colorectal cancer (mCRC) receiving anti-EGFR-based therapy: The PRESSING2 study

Management of BRCA Tumour Testing in an Integrated Molecular Tumour Board Multidisciplinary Model

Collaborators (6)

Tomoya Yokota

Giancarlo Pruneri

Adele Busico

Gian Paolo Dagrada

Monica Niger

Fabio Bozzi

Make your next move.